Copyright
©2011 Baishideng Publishing Group Co.
World J Clin Oncol. Jul 10, 2011; 2(7): 281-288
Published online Jul 10, 2011. doi: 10.5306/wjco.v2.i7.281
Published online Jul 10, 2011. doi: 10.5306/wjco.v2.i7.281
Table 4 Toxicities in trials comparing rituximab maintenance vs observation in follicular lymphoma
| Reference | No of. patients | Grade 3-4 AE | Neutropenia (grade 3-4) | Grade 3-4 Infections |
| Haisworth et al[16] | 62 | 9% vs 4% | 2% vs 0% | 0 |
| Ghielmini et al[14] Martinelli et al[19] | 185 | 28% vs 20% | 18% vs 17% | NA |
| Hochster et al[17] | 228 | NA | 3% vs 1% | 1% vs 1% |
| Forstpointner et al[10] | 105 | NA | 13% vs 6% | 4% vs 3% |
| van Oers et al[6] | 334 | NA | 10.8% vs 5.4%(P = 0.07) | 9% vs 2.4% (P = 0.009) |
| Salles et al[18,23] | 1018 | 23% vs 16% | 4% vs 1% | 4% vs 1% |
- Citation: Arcaini L, Merli M. Rituximab maintenance in follicular lymphoma patients . World J Clin Oncol 2011; 2(7): 281-288
- URL: https://www.wjgnet.com/2218-4333/full/v2/i7/281.htm
- DOI: https://dx.doi.org/10.5306/wjco.v2.i7.281